Please login to the form below

Not currently logged in

Akcea Therapeutics

This page shows the latest Akcea Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Novartis highlights emerging assets and late-stage pipeline at R&D day

Novartis highlights emerging assets and late-stage pipeline at R&D day

TQJ230, an antisense oligonucleotide it licensed from Akcea Therapeutics in February, which reduces Lp(a), a currently untreatable risk factor for cardiovascular disease – an outcomes trial of over 7, 500 patients

Latest news

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...